TCGA-AN-A0AM-01A-11R-A034-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 0
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.470
- INTERFERON_ALPHA_RESPONSE+0.450
- MTORC1_SIGNALING+0.440
- CHOLESTEROL_HOMEOSTASIS+0.410
- MYC_TARGETS_V1+0.400
- INTERFERON_GAMMA_RESPONSE+0.390
- GLYCOLYSIS+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.370
- ALLOGRAFT_REJECTION+0.350
Top 10 suppressed
- UV_RESPONSE_DN-0.440
- HEDGEHOG_SIGNALING-0.370
- TGF_BETA_SIGNALING-0.340
- MITOTIC_SPINDLE-0.210
- APICAL_JUNCTION-0.160
- ANGIOGENESIS-0.150
- HEME_METABOLISM-0.140
- WNT_BETA_CATENIN_SIGNALING-0.140
- NOTCH_SIGNALING-0.120
- TNFA_SIGNALING_VIA_NFKB-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20100231.Her2HRpos | — | C | 0.872 |
| 2 | TCGA-BA-A6DD-01A-12R-A31N-07 | — | — | 0.860 |
| 3 | TCGA-AO-A0J2-01A-11R-A034-07 | — | C | 0.851 |
| 4 | TCGA-BH-A0HB-01A-11R-A056-07 | — | B | 0.850 |
| 5 | BSR_02_0048_A10_S104 | — | C | 0.850 |
| 6 | sclc314571_S72.txt | — | cohortSQ1 | 0.850 |
| 7 | SRR33532822 | — | C | 0.843 |
| 8 | BS_996ZS2A4 | ATRT | — | 0.843 |
| 9 | TCGA-33-4589-01A-01R-1443-07 | — | cohortSQ1 | 0.836 |
| 10 | MDT-AP-0368 | Med | Medulloblastoma | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.470 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.410 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.370 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |